Xiang Li

Dr. Xiang Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Open access
PDF file
HZHuiqi Zong
Huiqi Zong
ZHZhekai Hu
Zhekai Hu
WLWeina Li
Weina Li
MWMina Wang
Mina Wang
QZQi Zhou
Qi Zhou
HLHongxu Liu
Hongxu Liu
Electronic cigarettes (e-cigarettes), as alternative nicotine delivery methods, has rapidly increased among youth and adults in recent years. However, cardiovascular safety is an important consideration regarding e-cigarettes usage. e-cigarette emissions, including nicotine, propylene glycol, flavorings, nitrosamine, and metals, might have adverse effects on cardiovascular health. A large body of epidemiological evidence has indicated that e-cigarettes are considered an independent risk factor for increased rates of cardiovascular disease occurrence and death. The incidence and mortality of various types of cardiovascular disease, such as cardiac arrhythmia, hypertension, acute coronary syndromes, and heart failure, have a modest growth in vapers (users of e-cigarettes). Although the underlying biological mechanisms have not been fully understood, studies have validated that oxidative stress, inflammation, endothelial dysfunction, atherosclerosis, hemodynamic effects, and platelet function play important roles in which e-cigarettes work in the human body. This minireview consolidates and discusses the epidemiological and biological links between e-cigarettes and various types of cardiovascular disease.

13 April 2024 in Complementary Therapies in Medicine
Verified
Journal Article
Open access
XSXueyan Sun
Xueyan Sun
JCJiaping Chen
Jiaping Chen
JSJuju Shang
Juju Shang
HLHongxu Liu
Hongxu Liu
XLXiang Li
Xiang Li
HZHuiwen Zhou
Huiwen Zhou
Traditional Chinese medicine injection for Activating Blood Circulation (TCMi-ABC), which exhibits comparable anticoagulant and antiplatelet effects, is commonly used as an adjuvant treatment for acute myocardial infarction (AMI) in China. The aim of this study was to conduct a meta-analysis to assess the efficacy and safety of TCMi-ABC in combination with conventional western medicine in reducing mortality associated with AMI. We conducted a comprehensive search of PubMed, Cochrane Library, EMBASE, Web of Science, CBM, WanFang Data, and CNKI databases. Randomized controlled trials (RCTs) investigating the use of TCMi-ABC (including Danhong injection, sodium tanshinone IIA sulfonate injection, salvia miltiorrhiza ligupyrazine injection, and puerarin injection) for the treatment of AMI were included. The search included studies published from the inception of the databases up to December 2022. Two authors independently screened RCTs, extracted data, and assessed the risk of bias. Meta-analysis was performed using RevMan 5.3 and Stata 17.0. The quality of evidence was evaluated using the GRADE approach. A total of 52 RCTs involving 5363 patients were included in the analysis, none of which described independent testing of the purity or potency of the TCMi-ABC product used. 19/52 reported random sequence generation. All RCTs lack adequate description of allocation concealment. 51/52 failed to assess blinding. The meta-analysis results demonstrated that the combined application of TCMi-ABC, compared with conventional western medicine treatment alone, significantly reduced in-hospital mortality in AMI patients [RR= 0.41, 95% CI (0.29, 0.59), P < 0.05], decreased the incidence of malignant arrhythmia [RR= 0.40, 95% CI (0.26, 0.61), P < 0.05], and increased left ventricular ejection fraction (LVEF) [MD= 5.53, 95% CI (3.81, 7.26), P < 0.05]. There was no significant difference in the incidence of adverse events between the two groups (P > 0.05). The GRADE evidence quality classification indicated that the evidence for in-hospital mortality, malignant arrhythmia, and adverse events was of moderate quality, while the evidence for LVEF was of low quality. TCMi-ABC demonstrates additional clinical value in reducing mortality and the risk of malignant arrhythmia in patients with AMI. However, further validation of these findings is warranted through high-quality clinical trials due to methodological weaknesses in randomization, blinding, allocation concealment, and insufficient assessing for the purity/potency of herbs and the gram amount of active constituents. [INPLASY], identifier [INPLASY202170082].

28 March 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HZHuiwen Zhou
Huiwen Zhou
JCJiaping Chen
Jiaping Chen
HLHongxu Liu
Hongxu Liu
XLXiang Li
Xiang Li
HZHuiqi Zong
Huiqi Zong
YLYunze Li
Yunze Li
Background: Traditional Chinese medicine injections for Tonifying Qi (TCMi-TQs), which exhibits comparable effect of regulating energy metabolism, is commonly used as an adjuvant treatment for acute myocardial infarction (AMI) in China.Objective: A systematic review and meta-analysis was conducted to contrast the effectiveness and safety of four TCMi-TQs in AMI.Methods: Eight Databases were thoroughly searched before 31 July 2024, for randomized controlled trials (RCTs) focusing on the application of TCMi-TQs combined with conventional treatments (CT) to treat AMI. The primary outcomes were in-hospital mortality and long-term mortality. Secondary outcomes included malignant arrhythmia, left ventricular ejection fraction (LVEF), and adverse events. Stata17.0 and RevMan 5.4.1 software were employed for meta-analysis. The quality of evidence was evaluated using the GRADE approach.Results: A total of 113 RCTs involving 10,779 patients were included in the analysis, none of which described in-dependent testing of the purity or potency of the TCMi-TQ product used. 51/113 reported random sequence generation. All RCTs lack adequate description of allocation concealment. 112/113 failed to assess blinding. The meta-analysis results demonstrated that the combined application of TCMi-TQ + CT, compared with CT, significantly reduced in-hospital mortality in AMI patients [RR = 0.58, 95% CI (0.51, 0.67), P < 0.05], decreased the incidence of malignant arrhythmia [RR = 0.51, 95%CI(0.42, 0.63), P < 0.05], increased LVEF [MD = 6.52, 95%CI(5.54, 7.50), P < 0.05], and decreased the incidence of adverse events [RR = 0.70, 95%CI(0.60, 0.81), P < 0.05]. The GRADE evidence quality classification indicated that the evidence for in-hospital mortality, malignant arrhythmia, and adverse events was of moderate quality, while the evidence for LVEF was of low quality.Conclusion: TCMi-TQ demonstrates additional clinical value in reducing mortality, the risk of malignant arrhythmia, and adverse events in patients with AMI. However, further validation of these findings is warranted through high-quality clinical trials due to methodological weaknesses in randomization, blinding, allocation concealment, and insufficient assessment of the purity/potency of botanical drugs and the quantity of active metabolites.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024573818, identifier PROSPERO (CRD42024573818).

4 August 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JCJiaping Chen
Jiaping Chen
HZHuiwen Zhou
Huiwen Zhou
HLHongxu Liu
Hongxu Liu
XLXiang Li
Xiang Li
HZHuiqi Zong
Huiqi Zong
YSYuxin Shi
Yuxin Shi
Background: Shenyuan Yiqi Huoxue Capsule (SYYQ) has clinical evidence to improve coronary microvascular dysfunction (CMD) by tonifying qi and removing blood stasis, but the underlying mechanism remains unclear.Objective: This study aims to explore the mechanism by which SYYQ alleviates CMD through a combination of network analysis and both in vivo and in vitro experiments.Methods: First, network pharmacology was employed to predict the mechanism of SYYQ on CMD. Building upon the findings of network pharmacology, we conducted in vivo experiment to verify the improvement mechanism of SYYQ in CMD rats using echocardiography, histopathology, serum biochemistry, TUNEL staining, and transmission electron microscopy (TEM). In the context of cell experiments, we evaluated the characteristic changes in mice cardiac microvascular endothelial cells (MCMECs) and the molecular mechanism of SYYQ through cell transfection, TEM, Western blotting, and qRT-PCR.Results: The results of network pharmacology suggest that SYYQ may enhance CMD through pathways related to apoptosis and vascular growth. Animal experiments demonstrated that SYYQ alleviated apoptosis, promoted microvascular opening, and reduced myocardial injury in CMD rats. Furthermore, cell experiments indicated that SYYQ mitigated apoptosis in hypoxic (Hyp) MCMECs, promoted the production of angiogenic factors. Furthermore, downregulation of miR-302-3p levels and activation of Hippo pathway were observed in Hyp MCMECs, which can be inhibited by SYYQ. When miR-302a-3p was overexpressed or the Hippo pathway was inhibited, the efficacy of SYYQ in promoting the production of angiogenic factors and inhibiting apoptosis in Hyp MCMECs was significantly enhanced. Additional studies revealed that miR-302a-3p negatively regulated LATS2.Conclusion: SYYQ improves CMD by promoting the production of angiogenic factors and inhibiting apoptosis via miR-302a-3p/Hippo.

17 June 2022 in Medicine
Verified
Journal Article
Open access
XLXiang Li
Xiang Li
YLYan Lou
Yan Lou
JSJuju Shang
Juju Shang
HLHongxu Liu
Hongxu Liu
JCJia-Ping Chen
Jia-Ping Chen
HZHui-Wen Zhou
Hui-Wen Zhou
Background: In spite of a growing number in the use of percutaneous coronary intervention (PCI) in China, the mortality of acute myocardial infarction (AMI) has not decreased. Traditional Chinese medicine injections for Activating Blood Circulation (TCMi-ABC), equivalent effect of anticoagulation or antiplatelet, are widely used in China; however, the improvement of fatality towards AMI is unclear. Therefore, we intend to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of TCMi-ABC in treatment with AMI. Methods: Based on the “National Medical Products Administration of China,” TCMi-ABC with AMI treatment indication will be selected, including Danhong injection, Sodium Tanshinone IIA Sulfonate injection, Danshen Chuanxiongqin injection, and Puerarin injection. Randomized controlled studies will be searched from as follows: PubMed, Embase, the CENTRAL in Cochrane Library, Chinese Biomedical Literature Database (SinoMed), China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and Wanfang Data Knowledge Service Platform. Two researchers will work independently on literature selection, data extraction, and quality assessment. The outcomes focus on the effects of TCMi-ABC on fatality of patients with AMI in hospitalization and in the long term, the incidence of malignant arrhythmia, left ventricular ejection fraction, and adverse events. RevMan 5.4.1 software was used for mate analysis. Results: This study will conduct a comprehensive literature search and provide a systematic synthesis of current published data to explore the efficacy and safety of TCMi-ABC for AMI. Conclusion: This study will provide high-quality evidence for treatment of AMI with TCMi-ABC in terms of efficacy and safety, which may help clinicians make a better complementary treatment schedule of patients with AMI.

4 August 2025 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
YLYunze Li
Yunze Li
JDJinlan Duan
Jinlan Duan
HLHongxu Liu
Hongxu Liu
SLSheng Lin
Sheng Lin
HXHongkun Xu
Hongkun Xu
XLXiang Li
Xiang Li
Background: Coronary microvascular dysfunction (CMD) in post-percutaneous coronary intervention (PCI) target vessels is increasingly recognized as a critical determinant of adverse cardiovascular outcomes, yet its prevalence and prognostic implications remain poorly characterized. We conducted a systematic review and meta-analysis to determine the prevalence of CMD in post-PCI target vessels and its associated clinical outcomes.Methods: We conducted a systematic review and meta-analysis of observational studies using quantitative coronary physiological assessments to evaluate CMD in post-PCI target vessels. Databases (PubMed, Embase, Web of Science) were searched from inception to January 2025. The pooled Prevalence, multivariable-adjusted hazard ratio (HR) and 95% confidence interval (CI) for clinical outcomes were calculated using random-effects models.Results: A total of 21 observational studies involving 6,632 patients were included. The pooled prevalence of CMD in post-PCI target vessels was 41.66% (95% CI: 34.18%–49.34%). Subgroup analyses revealed numerical variations in CMD prevalence across assessment methods, sex, clinical diagnoses, and target vessels, though intergroup differences did not reach statistical significance (all P > 0.05). The pooled prevalence of CMD was numerically higher in females (46.22% vs. 36.73% in males), patients with acute coronary syndrome (42.37% vs. 36.04% in chronic coronary syndrome), and those assessed via non-wire-based methods (44.72% vs. 35.65% in wire-based methods). CMD prevalence was comparable across target vessels (left anterior descending artery: 37.34%, left circumflex artery: 38.50%, right coronary artery: 39.09%). Patients with post-PCI thrombolysis in myocardial infarction (TIMI) flow grade ≤2 exhibited higher CMD prevalence than those with TIMI flow grade 3, with a statistically significant difference (75.36% vs. 37.26%, P = 0.0012). CMD in post-PCI target vessels was independently associated with a 3.10-fold increased risk of major adverse cardiovascular events (95% CI: 2.06–4.67) and a 4.66-fold risk of cardiac death or heart failure readmission (95% CI: 3.13–6.93).Conclusion: CMD in post-PCI target vessels is prevalent (approximately 40%) and independently associated with a elevated risk of adverse cardiovascular outcomes. Standardized diagnostic criteria and targeted interventions are urgently needed to improve outcomes in this population. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, PROSPERO CRD42025637496.